NR1H4 and hepatocellular carcinoma: Given this background, we evaluated the FXR agonist obeticholic acid (OCA) to mimic primary bile acids and 5β-cholanic acid 3 (5β-CA) to block the downstream signaling of secondary bile acids as an approach to treating HCC using an orthotopic HCC mouse model (Figure 1).